Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 6/20 | 0.45 |
| ▸ | F2 | P00734 | 5/20 | 0.45 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.43 |
| ▸ | ITGB3 | P05106 | 13/20 | 0.39 |
| ▸ | ITGA2B | P08514 | 13/20 | 0.39 |
| ▸ | ITGB2 | P05107 | 2/20 | 0.38 |
| ▸ | ITGAM | P11215 | 2/20 | 0.38 |
| ▸ | MIF | P14174 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7373273 | 0.79 | F2 (0.45) | F10F2PRSS1ITGB3ITGA2B | |
| SCHEMBL7213411 | 0.79 | ITGB3 (0.59) | ITGB3ITGA2B | |
| SCHEMBL7213270 | 0.75 | ITGB3 (0.53) | F10F2ITGB3ITGA2BMIF | |
| SCHEMBL29373935 | 0.69 | ITGB3 (0.71) | ITGB3ITGA2B | |
| SCHEMBL9030900 | 0.67 | F2 (0.58) | F10F2PRSS1ITGB3ITGA2B | |
| SCHEMBL7371172 | 0.61 | MIF (0.62) | F10F2ITGB3ITGA2BMIF | |
| SCHEMBL7219528 | 0.61 | ITGB3 (0.83) | ITGB3ITGA2B | |
| SCHEMBL12556241 | 0.59 | MIF (0.74) | F10F2PRSS1MIF | |
| SCHEMBL4158733 | 0.59 | KIF18A (0.49) | — | |
| SCHEMBL7373045 | 0.58 | MIF (0.72) | F10F2PRSS1ITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6185453-B1 | IONTOPHORETIC DEVICE INCLUDING SPECIFIED INTEGRIN INHIBITORS SUCH AS N3-(2-(3-(4-FORMAMIDINOPHENYL)-ISOXAZOLIN-5(R,S)-YL)-ACETYL)-N2 -(PHENYLSULFONYL)-2,3-(S)-DIAMINOPROPANOIC ACID | DUPONT PHARMACEUTICALS COMPANY | 2001-02-06 | — | — | US | claimed |
| US-6623981-B2 | Detecting antibodies which bind integrin bound modulators; obtain sample, incubate with modulators and antibodies, form complexes, screen for bound complex | BRISTOL-MYERS SQUIBB COMPANY | 2003-09-23 | — | — | US | disclosed |
| EP-1244911-A1 | AN IN VITRO PHAGOCYTOSIS METHOD TO PREDICT THE IN VIVO POTENTIAL OF INTEGRIN ANTAGONISTS/AGONISTS TO INDUCE THROMBOCYTOPENIA | Bristol-Myers Squibb Pharma Company (US) | 2002-10-02 | — | — | EP | disclosed |
| US-20020132276-A1 | FACS method for detecton of GPIIb/IIIa inhibitor dependent activators in plasma samples | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-09-19 | — | — | US | disclosed |
| US-20020081624-A1 | DETECTION OF PATIENTS AT RISK FOR DEVELOPING INTEGRIN ANTAGONIST/ AGONIST MEDIATED DISEASE STATES | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-06-27 | — | — | US | disclosed |
| WO-2001027617-A1 | AN IN VITRO PHAGOCYTOSIS METHOD TO PREDICT THE IN VIVO POTENTIAL OF INTEGRIN ANTAGONISTS/AGONISTS TO INDUCE THROMBOCYTOPENIA | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-04-19 | — | — | WO | disclosed |
| US-6185453-B1 | IONTOPHORETIC DEVICE INCLUDING SPECIFIED INTEGRIN INHIBITORS SUCH AS N3-(2-(3-(4-FORMAMIDINOPHENYL)-ISOXAZOLIN-5(R,S)-YL)-ACETYL)-N2 -(PHENYLSULFONYL)-2,3-(S)-DIAMINOPROPANOIC ACID | DUPONT PHARMACEUTICALS COMPANY | 2001-02-06 | — | — | US | disclosed |
| EP-0970950-A2 | Novel isoxazoline and isoxazole fibrinogen receptor antagonists | DuPont Pharmaceuticals Company (US) | 2000-01-12 | — | — | EP | disclosed |